Cargando…

Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors

Despite the burgeoning field of coronavirus disease-19 (COVID-19) research, the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibodies remains unclear. This study validated two high-throughput immunological methods for use as surrogate live virus neutrali...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnes, Thomas W., Schulte-Pelkum, Johannes, Steller, Laura, Filchtinski, Daniel, Jenness, Robin, Williams, Michelle R., Kober, Christina, Manni, Sandro, Hauser, Thomas, Hahn, Aaron, Kalina, Uwe, Simon, Toby L., Schuetz, Patrick, Roth, Nathan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489294/
https://www.ncbi.nlm.nih.gov/pubmed/34619377
http://dx.doi.org/10.1016/j.clim.2021.108871
_version_ 1784578322866372608
author Barnes, Thomas W.
Schulte-Pelkum, Johannes
Steller, Laura
Filchtinski, Daniel
Jenness, Robin
Williams, Michelle R.
Kober, Christina
Manni, Sandro
Hauser, Thomas
Hahn, Aaron
Kalina, Uwe
Simon, Toby L.
Schuetz, Patrick
Roth, Nathan J.
author_facet Barnes, Thomas W.
Schulte-Pelkum, Johannes
Steller, Laura
Filchtinski, Daniel
Jenness, Robin
Williams, Michelle R.
Kober, Christina
Manni, Sandro
Hauser, Thomas
Hahn, Aaron
Kalina, Uwe
Simon, Toby L.
Schuetz, Patrick
Roth, Nathan J.
author_sort Barnes, Thomas W.
collection PubMed
description Despite the burgeoning field of coronavirus disease-19 (COVID-19) research, the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibodies remains unclear. This study validated two high-throughput immunological methods for use as surrogate live virus neutralisation assays and employed them to examine the half-life of SARS-CoV-2 neutralising antibodies in convalescent plasma donations made by 42 repeat donors between April and September 2020. SARS-CoV-2 neutralising antibody titres decreased over time but typically remained above the methods' diagnostic cut-offs. Using this longitudinal data, the average half-life of SARS-CoV-2 neutralising antibodies was determined to be 20.4 days. SARS-CoV-2 neutralising antibody titres appear to persist in the majority of donors for several months. Whether these titres confer protection against re-infection requires further study and is of particular relevance as COVID-19 vaccines become widely available.
format Online
Article
Text
id pubmed-8489294
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-84892942021-10-04 Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors Barnes, Thomas W. Schulte-Pelkum, Johannes Steller, Laura Filchtinski, Daniel Jenness, Robin Williams, Michelle R. Kober, Christina Manni, Sandro Hauser, Thomas Hahn, Aaron Kalina, Uwe Simon, Toby L. Schuetz, Patrick Roth, Nathan J. Clin Immunol Article Despite the burgeoning field of coronavirus disease-19 (COVID-19) research, the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibodies remains unclear. This study validated two high-throughput immunological methods for use as surrogate live virus neutralisation assays and employed them to examine the half-life of SARS-CoV-2 neutralising antibodies in convalescent plasma donations made by 42 repeat donors between April and September 2020. SARS-CoV-2 neutralising antibody titres decreased over time but typically remained above the methods' diagnostic cut-offs. Using this longitudinal data, the average half-life of SARS-CoV-2 neutralising antibodies was determined to be 20.4 days. SARS-CoV-2 neutralising antibody titres appear to persist in the majority of donors for several months. Whether these titres confer protection against re-infection requires further study and is of particular relevance as COVID-19 vaccines become widely available. The Authors. Published by Elsevier Inc. 2021-11 2021-10-04 /pmc/articles/PMC8489294/ /pubmed/34619377 http://dx.doi.org/10.1016/j.clim.2021.108871 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Barnes, Thomas W.
Schulte-Pelkum, Johannes
Steller, Laura
Filchtinski, Daniel
Jenness, Robin
Williams, Michelle R.
Kober, Christina
Manni, Sandro
Hauser, Thomas
Hahn, Aaron
Kalina, Uwe
Simon, Toby L.
Schuetz, Patrick
Roth, Nathan J.
Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors
title Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors
title_full Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors
title_fullStr Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors
title_full_unstemmed Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors
title_short Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors
title_sort determination of neutralising anti-sars-cov-2 antibody half-life in covid-19 convalescent donors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489294/
https://www.ncbi.nlm.nih.gov/pubmed/34619377
http://dx.doi.org/10.1016/j.clim.2021.108871
work_keys_str_mv AT barnesthomasw determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors
AT schultepelkumjohannes determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors
AT stellerlaura determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors
AT filchtinskidaniel determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors
AT jennessrobin determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors
AT williamsmicheller determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors
AT koberchristina determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors
AT mannisandro determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors
AT hauserthomas determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors
AT hahnaaron determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors
AT kalinauwe determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors
AT simontobyl determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors
AT schuetzpatrick determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors
AT rothnathanj determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors